Weight-Adjusted Dosing of 3-OHB in Patients With Chronic Heart Failure (KINETICS2)
Heart Failure, Ketosis
About this trial
This is an interventional treatment trial for Heart Failure focused on measuring Hemodynamics
Eligibility Criteria
Inclusion criteria: Chronic HF: NYHA class II-III, left ventricular ejection fraction (LVEF) <40%
Exclusion Criteria: Diabetes or HbA1c >48 mmol/mol, significant cardiac valve disease, severe stable angina pectoris, severe comorbidity as judged by the investigator, inability to give informed consent
Sites / Locations
- Aarhus University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Placebo Comparator
Active Comparator
Ketone Monoester
Placebo Treatment
Ketone Monoester in presence of low-dose insulin clamp
Weight-adjusted dose of 3-OHB Monoester (KetoneAID KE4, Virginia, US) 0.5 g/kg (max 50 g)
Maltodextrin-based placebo (Science In Sport, UK) in isocaloric dose to the experimental arm.
Same as experimental arm, but in the presence of a low-dose insulin clamp to suppress free fatty acid metabolism